{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.22","estimateComment":"T+OFS was the reference group in the estimation of the hazard ratio","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.84","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.1","upperLimit":"94.3","value":"93.3"},{"groupId":"OG001","lowerLimit":"92.2","upperLimit":"94.4","value":"93.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1328"},{"groupId":"OG001","value":"1332"}],"units":"Participants"}],"description":"Estimated percentage of patients alive at 8 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG000","title":"T+OFS"},{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG001","title":"E+OFS"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"8-year estimates, reported at a median follow-up of 9 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}